Home > Insider Trading > Filing (0001209191-23-004945)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1706431	Vir Biotechnology Inc.	VIR	Biological Products, (No Disgnostic Substances) (2836)	812730369

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1787370	Phillip Pang	C/O Vir Biotechnology, Inc. 499 Illinois Street, Suite 500 San Francisco CA 94158	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2023-01-24	25,406	$1.58	169,406	No	4	A	Direct
Common Stock	Acquisiton	2023-01-24	4,594	$5.18	174,000	No	4	A	Direct
Common Stock	Disposition	2023-01-24	30,000	$30.00	144,000	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2023-01-24	25,406	$0.00	25,406	$1.58
Common Stock	Stock Option (Right to Buy)	Disposition	2023-01-24	4,594	$0.00	4,594	$5.18

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
13,576		2028-07-19	No	4	M	Direct
37,535		2029-03-11	No	4	M	Direct

Footnotes

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 28, 2022.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
1/4 of the shares subject to the stock option vested and became exercisable on July 19, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.
1/4 of the shares subject to the stock option vested and became exercisable on March 11, 2020, and the remaining shares vest in 36 equal monthly installments thereafter.